(Q34579641)

English

Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

phase III clinical trial

0 references

non-small-cell lung carcinoma

1 reference

based on heuristic

inferred from title

Alessandro Morabito

18

object named as

Alessandro Morabito

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Cesare Gridelli

1

object named as

Cesare Gridelli

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Fortunato Ciardiello

6

object named as

Fortunato Ciardiello

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Domenico Galetta

10

object named as

Domenico Galetta

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

5

object named as

Teresa Gamucci

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

author name string

Ciro Gallo

2

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Anna Ceribelli

3

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Vittorio Gebbia

4

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Francesco Carozza

7

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Adolfo Favaretto

8

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Bruno Daniele

9

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Santi Barbera

11

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Francesco Rosetti

12

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Antonio Rossi

13

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Paolo Maione

14

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Francesco Cognetti

15

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Antonio Testa

16

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Massimo Di Maio

17

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Francesco Perrone

19

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

GECO investigators

20

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 June 2007

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

500-512

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970146-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970146-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970146-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970146-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970146-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970146-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970146-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Prolonged gemcitabine infusion in advanced non-small cell lung carcinoma: a randomized phase II study of two different schedules in combination with cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970146-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical implications of prostaglandin and thromboxane A2 formation (1).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970146-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical implications of prostaglandin and thromboxane A2 formation (2).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970146-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970146-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Differential regulation of cyclooxygenases 1 and 2 by interleukin-1 beta, tumor necrosis factor-alpha, and transforming growth factor-beta 1 in human lung fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970146-8

7 January 2021

based on heuristic

inferred from DOI database lookup

COX-2 is expressed in human pulmonary, colonic, and mammary tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970146-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclooxygenase, NSAIDs, and colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970146-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Host cyclooxygenase-2 modulates carcinoma growth.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970146-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970146-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Selective cyclooxygenase-2 inhibitors and non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970146-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970146-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisal

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970146-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970146-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy M

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970146-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970146-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical T

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970146-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970146-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlates.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970146-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970146-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970146-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970146-8

7 January 2021

based on heuristic

inferred from DOI database lookup

COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970146-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk of cardiovascular events and rofecoxib: cumulative meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970146-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970146-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Interpreting the significance of changes in health-related quality-of-life scores.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970146-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Supportive care in patients with advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970146-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Did targeted therapy fail cyclooxygenase too?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970146-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970146-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(07)70146-8

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34579641&oldid=1768038941"